A mutated RAS gene is found in some types of cancer ... Yuan explained, “we are always looking for mutations, but we must not forget to think about how to stop signaling pathways that drive tumor ...

Assessment of transfer entropy is useful for network analysis of cell signaling network providing information on the network topology and action points of genetic mutations and drug effect, thus will ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

Research led by York University's Faculty of Health reveals how a specific mutation in a protein called TRAF1 can shut down ...

About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

A single cellular pathway helps drive almost one in four ... as a central master switch,” Lipford says. “Cancer-causing mutations leave this protein stuck in the on position, which can cause ...

A Deep Cyclic Inhibitor (DCI) of the mitogen-activated protein kinase (MAPK) pathway, IMM-6-415 ... for a broad patient population with RAS or RAF mutations. “We look forward to sharing initial ...

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...